OBJECTIVE: Gap in knowledge on benefit/risk ratio of second generation antipsychotics (SGA) in the paediatric population represents a challenge for the scientific community. This study aims to analyse all suspected adverse drug reactions (ADRs) to SGA observed during the study period; compare the safety profiles of risperidone and aripiprazole; evaluate the effect of switching from risperidone to aripiprazole or to a first generation antipsychotic (FGA). METHODS: Prospective analysis of spontaneously reported ADRs concerning 184 paediatric outpatients between 2012 and 2014.; clinical outcomes of drug switch were evaluated. RESULTS: Out of the 184 patients, 130 experienced at least one ADR; ADRs were usually not serious and more frequently associated with aripiprazole. Switching to aripiprazole was associated with better results than switching to FGAs in the Clinical Global Impression scale- Efficacy (CGI-E) scores (p = 0.018), Disturbed behaviour checklist-parents (DBC-P) self-absorption subscale (p = 0.010); only a trend for difference between changing to aripiprazole vs FGAs in the DBC-P total score (p = 0.054) and social relating subscale (p = 0.053) was observed. CONCLUSIONS: SGAs safety data were consistent with the ones already known; however, there is still a need to improve the knowledge in pharmacovigilance field among clinicians. Switching to aripiprazole may be a valid alternative to risperidone.

Second generation antipsychotics in 'real-life' paediatric patients : adverse drug reactions and clinical outcomes of drug switch / C. Rafaniello, M. Pozzi, S. Pisano, C. Ferrajolo, S. Bertella, L. Sportiello, C. Carnovale, M.G. Sullo, D. Cattaneo, M. Gentili, R. Rizzo, A. Pascotto, E. Mani, L. Villa, M.P. Riccio, S. Sperandeo, R. Bernardini, C. Bravaccio, E. Clementi, M. Molteni, F. Rossi, S. Radice, A. Capuano. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 15:suppl. 2(2016 Dec), pp. 1-8. [10.1080/14740338.2016.1229301]

Second generation antipsychotics in 'real-life' paediatric patients : adverse drug reactions and clinical outcomes of drug switch

M. Pozzi
Secondo
;
C. Carnovale;D. Cattaneo;M. Gentili;E. Clementi;M. Molteni;S. Radice
Penultimo
;
2016

Abstract

OBJECTIVE: Gap in knowledge on benefit/risk ratio of second generation antipsychotics (SGA) in the paediatric population represents a challenge for the scientific community. This study aims to analyse all suspected adverse drug reactions (ADRs) to SGA observed during the study period; compare the safety profiles of risperidone and aripiprazole; evaluate the effect of switching from risperidone to aripiprazole or to a first generation antipsychotic (FGA). METHODS: Prospective analysis of spontaneously reported ADRs concerning 184 paediatric outpatients between 2012 and 2014.; clinical outcomes of drug switch were evaluated. RESULTS: Out of the 184 patients, 130 experienced at least one ADR; ADRs were usually not serious and more frequently associated with aripiprazole. Switching to aripiprazole was associated with better results than switching to FGAs in the Clinical Global Impression scale- Efficacy (CGI-E) scores (p = 0.018), Disturbed behaviour checklist-parents (DBC-P) self-absorption subscale (p = 0.010); only a trend for difference between changing to aripiprazole vs FGAs in the DBC-P total score (p = 0.054) and social relating subscale (p = 0.053) was observed. CONCLUSIONS: SGAs safety data were consistent with the ones already known; however, there is still a need to improve the knowledge in pharmacovigilance field among clinicians. Switching to aripiprazole may be a valid alternative to risperidone.
adverse drug reactions; aripiprazole; pharmacovigilance; risperidone; second-generation antipsychotics
Settore BIO/14 - Farmacologia
dic-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
Second generation antipsychotics in ‘real.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 239.68 kB
Formato Adobe PDF
239.68 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/485874
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 21
social impact